ARROW [72] is a multi-cohort, open-label, phase I/II study evaluating the safety, tolerability, and antitumor activity of pralsetinib, a highly active oral selective RET inhibitor, in patients with RET fusion gene positive NSCLC. Here, RET is linked to non-small cell lung carcinoma.